Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States (Clin Cardiol. 2016;39:309–367). In Figure 1, the cell labeled “CVD” should have been labeled “No CVD events.” In Table 1, the 10‐year risk of ≥ 1 CVD event should have been 51% for HeFH, 44% for ASCVD, and 51% for ASCVD with statin intolerance. Also in Table 1, the proportion of patients who are secondary prevention appears twice, and the redundant row (labeled “Secondary prevention % patients”) has been deleted from the online version. The corrected article is available on the Clinical Cardiology website.
Erratum, Clin Cardiol, 2016, 39, 621, DOI: 10.1002/clc.22589